Terns Pharma, a California-Shanghai startup, acquired greater China rights to a treatment for liver disease developed by Genfit of France in an agreement worth up to $228 million. Elafibranor is a dual peroxisome proliferator-activated alpha/delta (PPAR α/δ ) agonist currently in US Phase III trials. Terns will have rights to develop elafibranor to treat non-alcoholic steatohepatitis (NASH) and primary biliary cholangitis (PBC) in China. A liver disease and cancer company, Terns will make a $35 million upfront payment to Genfit, with the rest being regulatory and sales milestones. More details....
Share this with colleagues:
Original Article: Terns Enters $228 Million Agreement with Genfit for NASH Candidate